绝经后Luminal B型乳腺癌的内分泌治疗  

Aromatase inhibitors and TAM in the treatment of post-menopausal Luminal B breast cancer patients

作　　者：张晶虹[1] 刘艳[2] 郝晓甍[2] 惠锐[2] 臧凤林[2] 刘鹏[2] 朱元喜[2] 杨毅[2] 张瑾[2] 

机构地区：[1]首都医科大学附属北京同仁医院普外科,100730 [2]天津医科大学附属肿瘤医院乳腺科

出　　处：《中华普通外科杂志》2010年第6期449-452,共4页Chinese Journal of General Surgery

基　　金：天津市应用基础与前沿技术研究计划重点项目（编号：08JCZDJC23800）

摘　　要：目的 探讨芳香化酶抑制剂和三苯氧胺对绝经后Luminal B型乳腺癌患者的疗效.方法 收集天津市肿瘤医院2002年7月至2005年3月间733例术后接受辅助内分泌治疗的原发性乳腺癌患者资料,肿瘤性质均经手术切除病理组织学证实.患者均为绝经后且ER阳性,其中501例接受三苯氧胺治疗,232例接受芳香化酶抑制剂治疗.采用免疫组化SP法进行ER、PR、HER2检测.随访时间36～90个月,中位随访时间46个月.结果 芳香化酶抑制剂治疗组Luminal B型乳腺癌患者三年无瘤生存率高于三苯氧胺组（90.6% vs.88.6%,P=0.038）.三苯氧胺组亚组分析显示：LN＋/HER2＋患者三年无瘤生存率低于LN＋/HER2-患者（88.2% vs 90.4%,P=0.037） HER2＋/PR＋患者高于HER2＋/PR-患者（90.8% vs.89.5%,P=0.032）.芳香化酶抑制剂组内LN（＋）和LN（-）亚组中,HER2（＋）患者与HER2（-）患者的三年无瘤生存率差异均无统计学意义（P〉0.05） 而HER2＋/PR＋组高于HER2＋/PR-组（91.9% vs.90.5%,P=0.029）.芳香化酶抑制剂组潮热、阴道出血、静脉血栓形成的发生率低,肌肉骨骼疼痛、骨折的发生率则高于三苯氧胺组（P〈0.05）.结论 芳香化酶抑制剂对绝经后Luminal B型患者疗效好于三苯氧胺,此效果不受患者腋窝淋巴结状态的影响,且耐受性和安全性较好.Objective To evaluate a therapeutic strategy using aromatase inhibitors and TAM in postmenopausal Luminal B breast cancer patients. Methods The clinical data of 733 primary breast cancer cases receiving postoperative endocrine thempy from July 2002 to Mar 2005 in Tianjin Cancer Hospital were retrospectively analyzed.Diagnosis was confirmed by pathology in all the cases.All patients were post-menopausal and ER-positive.501 patients were given tamoxifen（TAM 2.5 mg qd,po）,232 patients were given aromatase inhibitors（Letrozole 10 mg bid,po）.The follow-up time ranged from 36 to 90 months.Median follow-up time was 46 months.Results The disease-free-survival（DFS）rate of Luminal B breast cancer patients in aromatase inhibitors（AIS）group was higherthan that in TAM group（90.6% vs.88.6%,P=0.038）.In TAM group,subgroup analysis showed 3-year DFS of node-positive with HER2（＋）is lower than that of node-positive with Her-2-negative（88.2% vs.90.4%,P=0.037） 3-year DFS of ER＋/PR＋ group in HER2（＋） patients was higher than that of ER＋/PR-group（90.8% vs.89.5%.P=0.032）.In AIs group,in spite of the axillary lymph node status,there was no significant difference of 3-year DFS between HER2（＋）patients and HER2（-）ones（P〉0.05）.3-year DFS of ER＋/PR＋with HER2（＋） patients was higher than that of ER＋/PR-ones with HER2（＋）（91.9% vs.90.5%,P=0.029）.Hot flush,vaginal bleeding and thromboembolics in AIS group is less frequent,but muscle pain and bone fracture is more common than that in TAM group（P〈0.05）.Conclusion Compared to TAM, AIs is more effective and safer with postmenopausal Luminal B patients,and the effect is independent on node stams.

关 键 词：乳腺肿瘤 基因 ERBB-2 芳香酶抑制剂 三苯氧胺 内分泌治疗 

分 类 号：R737.9[医药卫生—肿瘤]